Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. Show more
Location: 2749 East Parleys Way, Salt Lake City, UT, 84109, United States | Website: https://www.sera.com | Industry: Medical Devices | Sector: Healthcare
Market Cap
107M
52 Wk Range
$1.37 - $9.13
Previous Close
$2.76
Open
$2.77
Volume
59,444
Day Range
$2.71 - $2.84
Enterprise Value
58.72M
Cash
46.2M
Avg Qtr Burn
-6.684M
Insider Ownership
11.53%
Institutional Own.
69.95%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|